Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines [Seeking Alpha]
Kodiak Sciences (KOD) had its price target raised by UBS Group AG from $50.00 to $80.00. They now have a "buy" rating on the stock.
Kodiak Sciences (KOD) had its "buy" rating reaffirmed by HC Wainwright. They now have a $58.00 price target on the stock, up from $38.00.
Kodiak Sciences (KOD) CLimbs 75% on Stellar Clinical Results [Yahoo! Finance]
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham [Yahoo! Finance]